Prostvac
Prostvac is an investigational immunotherapy for the treatment of prostate cancer. It is being developed by Bavarian Nordic, a biotechnology company specializing in vaccines.
Overview[edit | edit source]
Prostvac uses a virus as a vector to deliver antigens to the immune system. The antigens are designed to stimulate an immune response against prostate-specific antigen (PSA), a protein that is overexpressed in prostate cancer cells.
Clinical Trials[edit | edit source]
Prostvac has been tested in several clinical trials. In a Phase II trial, Prostvac was shown to extend the median survival of patients with metastatic castration-resistant prostate cancer by 8.5 months compared to a placebo. However, a subsequent Phase III trial did not meet its primary endpoint of improving overall survival.
Mechanism of Action[edit | edit source]
Prostvac works by stimulating the body's immune system to attack prostate cancer cells. It does this by using a virus to deliver antigens to the immune system. These antigens are designed to stimulate an immune response against prostate-specific antigen (PSA), a protein that is overexpressed in prostate cancer cells.
Side Effects[edit | edit source]
The most common side effects of Prostvac are flu-like symptoms, including fever, chills, and fatigue. These symptoms are typically mild and temporary.
See Also[edit | edit source]
Prostvac Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD